company background image
RGS

Regeneus ASX:RGS Stock Report

Last Price

AU$0.06

Market Cap

AU$18.4m

7D

7.1%

1Y

-21.1%

Updated

03 Jul, 2022

Data

Company Financials
RGS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

RGS Stock Overview

Regeneus Ltd, a clinical-stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases in Australia.

Regeneus Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneus
Historical stock prices
Current Share PriceAU$0.06
52 Week HighAU$0.094
52 Week LowAU$0.041
Beta0.26
1 Month Change30.44%
3 Month Change7.14%
1 Year Change-21.05%
3 Year Change-36.84%
5 Year Change-52.00%
Change since IPO-77.78%

Recent News & Updates

Shareholder Returns

RGSAU BiotechsAU Market
7D7.1%-0.6%-0.5%
1Y-21.1%-8.7%-12.2%

Return vs Industry: RGS underperformed the Australian Biotechs industry which returned -8.7% over the past year.

Return vs Market: RGS underperformed the Australian Market which returned -12.2% over the past year.

Price Volatility

Is RGS's price volatile compared to industry and market?
RGS volatility
RGS Average Weekly Movement10.9%
Biotechs Industry Average Movement10.4%
Market Average Movement9.9%
10% most volatile stocks in AU Market16.6%
10% least volatile stocks in AU Market4.4%

Stable Share Price: RGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: RGS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aKarolis Rosickashttps://regeneus.com.au

Regeneus Ltd, a clinical-stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases in Australia. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing.

Regeneus Fundamentals Summary

How do Regeneus's earnings and revenue compare to its market cap?
RGS fundamental statistics
Market CapAU$18.39m
Earnings (TTM)-AU$4.35m
Revenue (TTM)AU$871.28k

21.1x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGS income statement (TTM)
RevenueAU$871.28k
Cost of RevenueAU$0
Gross ProfitAU$871.28k
Other ExpensesAU$5.22m
Earnings-AU$4.35m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin100.00%
Net Profit Margin-499.18%
Debt/Equity Ratio52.8%

How did RGS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGS?

Other financial metrics that can be useful for relative valuation.

RGS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20.7x
Enterprise Value/EBITDA-3.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does RGS's PS Ratio compare to its peers?

RGS PS Ratio vs Peers
The above table shows the PS ratio for RGS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14.1x
1AD AdAlta
4.4xn/aAU$17.3m
PAB Patrys
15.6xn/aAU$43.2m
DXB Dimerix
9xn/aAU$40.1m
BDX BCAL Diagnostics
27.3xn/aAU$16.6m
RGS Regeneus
21.1xn/aAU$18.4m

Price-To-Sales vs Peers: RGS is expensive based on its Price-To-Sales Ratio (21.1x) compared to the peer average (14.1x).


Price to Earnings Ratio vs Industry

How does RGS's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Sales vs Industry: RGS is expensive based on its Price-To-Sales Ratio (21.1x) compared to the Australian Biotechs industry average (21.1x)


Price to Sales Ratio vs Fair Ratio

What is RGS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RGS's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of RGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RGS's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Regeneus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regeneus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of RGS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Regeneus competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Regeneus performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RGS is currently unprofitable.

Growing Profit Margin: RGS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RGS is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare RGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: RGS has a negative Return on Equity (-181.9%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Regeneus's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RGS's short term assets (A$2.7M) exceed its short term liabilities (A$2.0M).

Long Term Liabilities: RGS's short term assets (A$2.7M) exceed its long term liabilities (A$47.6K).


Debt to Equity History and Analysis

Debt Level: RGS has more cash than its total debt.

Reducing Debt: Insufficient data to determine if RGS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RGS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RGS has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.4% each year.


Discover healthy companies

Dividend

What is Regeneus's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Karolis Rosickas

1.67yrs

Tenure

AU$658,298

Compensation

Mr. Karolis Rosickas serves as Chief Executive Officer at Regeneus Ltd since November 2, 2020. He is an experienced executive and healthcare entrepreneur with business experience in healthcare, technology...


CEO Compensation Analysis

Compensation vs Market: Karolis's total compensation ($USD446.85K) is above average for companies of similar size in the Australian market ($USD281.90K).

Compensation vs Earnings: Insufficient data to compare Karolis's compensation with company performance.


Leadership Team

Experienced Management: RGS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: RGS's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RGS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Regeneus Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Regeneus Ltd
  • Ticker: RGS
  • Exchange: ASX
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$18.386m
  • Shares outstanding: 306.44m
  • Website: https://regeneus.com.au

Location

  • Regeneus Ltd
  • 2 Paddington Street
  • Paddington
  • New South Wales
  • 2021
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.